The mean duration of follow-up was 39.9 months (SD = 9.3 months) in the semaglutide 2.4 mg group and 39.7 months (SD = 9.5 months) in the placebo group
Christian Hendershot, director of clinical research at the USC Institute for Addiction Science and the study's first author
Monitoring nutritional intake is important, especially for those with other health conditions
However, despite encouraging preclinical results, clinical translation remains limited and will likely require combined strategies that address both upstream immune dysregulation (to induce tolerance) and ongoing symptoms
Am J Physiol Endocrinol Metab 273: E981-988, 1997
It is crucial to further investigate the diverse roles played by neutrophils in hostmicrobiota interactions, both at steady state and in inflammatory conditions, to develop new IBD therapies